Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RO7247669 alone or with tiragolumab versus atezolizumab in first-line platinum-ineligible advanced urothelial bladder cancer
2022-002265-15Phase 2Active
- Sponsor
- Roche
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) comparing RO7247669 monotherapy, RO7247669 plus tiragolumab and Atezolizumab control (3 arms). Primary endpoint: Confirmed objective response rate. Started Oct 2022; status: active.
02
Drugs
tobemstomigtiragolumabatezolizumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2022-002265-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002265-15.